0.336
-0.01 (-3.64%)
| Penutupan Terdahulu | 0.349 |
| Buka | 0.340 |
| Jumlah Dagangan | 1,867,129 |
| Purata Dagangan (3B) | 4,208,578 |
| Modal Pasaran | 41,851,088 |
| Harga / Jualan (P/S) | 1.33 |
| Harga / Buku (P/B) | 32.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 - 12 May 2025 |
| Margin Keuntungan | -217.63% |
| Margin Operasi (TTM) | -890.05% |
| EPS Cair (TTM) | -0.590 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -70.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3,005.34% |
| Nisbah Semasa (MRQ) | 1.83 |
| Aliran Tunai Operasi (OCF TTM) | -79.01 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.67 M |
| Pulangan Atas Aset (ROA TTM) | -30.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -505.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Mersana Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 3.13 |
|
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.48% |
| % Dimiliki oleh Institusi | 72.23% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Truist Securities, 2,877.96%) | Beli |
| Median | 7.50 (2,133.47%) | |
| Rendah | 5.00 (Guggenheim, 1,388.98%) | Beli |
| Purata | 7.50 (2,133.47%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.340 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 16 May 2025 | 5.00 (1,388.98%) | Beli | 0.340 |
| Truist Securities | 16 May 2025 | 10.00 (2,877.96%) | Beli | 0.340 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |